Business Context and Reporting Period
This Form 8-K Current Report was filed by Aquestive Therapeutics, Inc. on April 1, 2024. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors, effective April 1, 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Composition: The Board of Directors was increased from seven members to eight members.
- Independence: Seven of the eight directors are now independent.
- Committee Assignment: The new director was appointed to the Nominating and Corporate Governance Committee.
Management Commentary and Compensation
Abigail L. Jenkins was appointed as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. The Board determined she qualifies as an "independent director" under Nasdaq rules. In connection with her appointment, Ms. Jenkins will receive 57,000 stock options under the Company's 2018 Equity Incentive Plan. These options have an exercise price equal to the closing market price on the grant date and vest in annual equal one-third increments commencing on the first anniversary of the grant date.
Investor Verification Checklist
- Verify the closing market price of Aquestive Therapeutics common stock on April 1, 2024, to determine the exercise price of the granted options.
- Review the Company's 2023 Proxy Statement for the full details of the non-employee director compensation program.
- Confirm the total number of outstanding shares and the potential dilution impact of the 57,000 new options.
- Check subsequent filings for any changes to the Board composition or committee assignments.